← All Day One Biopharmaceuticals, INC filings

Day One Biopharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
DAWN
Day One Biopharmaceuticals, INC
10-K/A: Day One Biopharmaceuticals 10-K/A Filing Summary
Day One Biopharmaceuticals filed an amendment to its 2025 Annual Report to include required Part II and Part III disclosures and updated Sarbanes-Oxley certifications.
NASDAQ
DAWN
Day One Biopharmaceuticals, INC
10-K: Day One Biopharma's OJEMDA Drives Revenue, Expands Oncology Pipeline
Day One Biopharmaceuticals reports significant revenue growth from its newly approved pediatric brain tumor therapy, OJEMDA, while strategically expanding its oncology pipeline through key acquisitions and licensing deals.
NASDAQ
DAWN
Day One Biopharmaceuticals, INC
10-K/A: Day One Biopharmaceuticals Amends 10-K Filing to Correct Accounting Firm Consent and Audit Report References
Day One Biopharmaceuticals files an amendment to its 2024 annual report to correct errors in the independent accounting firm's consent and references within the audit reports.
NASDAQ
DAWN
Day One Biopharmaceuticals, INC
10-K: Day One Biopharmaceuticals Reports 2024 Results, Highlights OJEMDA Launch and Ipsen Deal
Day One Biopharmaceuticals announces its 2024 financial results, emphasizing the commercial launch of OJEMDA and a strategic licensing agreement with Ipsen.
NASDAQ
DAWN
Day One Biopharmaceuticals, INC
10-K: Day One Biopharmaceuticals Reports Full Year 2023 Results and Provides Business Update
Day One Biopharmaceuticals is advancing its pipeline with a focus on pediatric cancer, highlighted by positive Phase 2 data for tovorafenib and ongoing Phase 3 trial.